{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:30:59Z","timestamp":1760315459675,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,5,14]],"date-time":"2007-05-14T00:00:00Z","timestamp":1179100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>This study was a noncomparative, multicenter, phase II study. Between March 2000 and December 2002, 54 patients with recurrent FL were enrolled in the FC+R trial. Patients received fludarabine at a dose of 25 mg\/m<jats:sup>2<\/jats:sup> and cyclophosphamide at a dose of 300 mg\/m<jats:sup>2<\/jats:sup> daily for 3 consecutive days, every 3 weeks for 4 cycles. Rituximab was administered at a dose of 375 mg\/m<jats:sup>2<\/jats:sup> beginning 2 weeks after the first course of fludarabine and cyclophosphamide and then on Day 1 of each cycle thereafter. The planned treatment duration was 10 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Overall, 92% of patients completed the planned therapy in 10 to 14 weeks and 74% achieved a complete response (CR). Among patients with BCL2\u2012positive bone marrow, 86% obtained a molecular disease remission (MR). The median survival from treatment (SFT), the duration of disease remission (DR), and time to disease progression (TTP) had not been reached after a median follow\u2012up of 45 months. Of the baseline characteristics, &gt;2 previous treatments, BCL2\u2012positive bone marrow, and low Follicular Lymphoma International Prognostic Index (FLIPI) score were found to be associated with better DR and\/or TTP. Hematologic toxicity was transient and reversible, with the exception of 3 patients with severe and prolonged neutropenia. Three patients presented with infections, 1 of whom died of bronchopneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The FC+R scheme, a nonanthracycline\u2012containing regimen lasting up to 10 weeks, was found to be relatively well\u2012tolerated and demonstrated significant antilymphoma activity with excellent clinical CR and molecular response rates. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22740","type":"journal-article","created":{"date-parts":[[2007,5,14]],"date-time":"2007-05-14T11:27:59Z","timestamp":1179142079000},"page":"121-128","source":"Crossref","is-referenced-by-count":35,"title":["Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma"],"prefix":"10.1002","volume":"110","author":[{"given":"Stefano","family":"Sacchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Brugiatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Italian Lymphoma Study Group (GISL)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_6_3_2","first-page":"669","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"9","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1016\/j.blre.2005.11.003"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1038\/sj.leu.2400849"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_2","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"e_1_2_6_7_2","first-page":"1005","article-title":"Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies","volume":"43","author":"Adkins JC","year":"1997","journal-title":"Drugs."},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_2","DOI":"10.1200\/jco.2003.05.128"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_2","DOI":"10.1200\/JCO.2005.06.146"},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_2","DOI":"10.1200\/JCO.2005.03.1674"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_2","DOI":"10.1200\/JCO.2004.04.020"},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_2","DOI":"10.1200\/JCO.2005.03.3696"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_2","DOI":"10.1200\/JCO.1998.16.8.2825"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1200\/JCO.2005.02.172"},{"key":"e_1_2_6_15_2","first-page":"951","article-title":"Clinical activity and safety of combination immunotherapy with interferon\u2010\u03b12a and rituximab in patients with relapsed low grade non Hodgkin's lymphoma","volume":"86","author":"Sacchi S","year":"2001","journal-title":"Haematologica."},{"key":"e_1_2_6_16_2","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B\u2010non\u2010Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down\u2010regulation of Bcl\u20102 and sensitization to cytotoxic drugs","volume":"61","author":"Alas S","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_6_17_2","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down\u2010regulation of Bcl\u20102 and sensitization of B\u2010cell non\u2010Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas S","year":"2001","journal-title":"Clin Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_2","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B cell chronic lymphocytes leukemia","volume":"94","author":"Bellosillo B","year":"1999","journal-title":"Blood."},{"doi-asserted-by":"publisher","key":"e_1_2_6_20_2","DOI":"10.1182\/blood.V83.12.3800.3800"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_2","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_22_2","first-page":"445","volume-title":"Manual of Oncologic Therapeutics","author":"Wittes RE","year":"1995"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_2","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_24_2","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel N","year":"1959","journal-title":"J Natl Cancer Inst."},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_2","DOI":"10.1214\/aoms\/1177730491"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_2","DOI":"10.1182\/blood-2003-12-4434"},{"issue":"12","key":"e_1_2_6_27_2","first-page":"G17","article-title":"BACOP\/FND first\u2010line treatment of follicular lymphoma. Multicentric study of GISL. Preliminary result","volume":"15","author":"Luisi D","year":"2004","journal-title":"Ann Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_6_28_2","DOI":"10.1200\/JCO.2002.11.068"},{"doi-asserted-by":"publisher","key":"e_1_2_6_29_2","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_6_30_2","first-page":"282","article-title":"Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low\u2010grade non\u2010Hodgkin's lymphoma","volume":"86","author":"Santini G","year":"2001","journal-title":"Haematologica."},{"doi-asserted-by":"publisher","key":"e_1_2_6_31_2","DOI":"10.1182\/blood-2005-01-0016"},{"doi-asserted-by":"publisher","key":"e_1_2_6_32_2","DOI":"10.1182\/blood-2006-05-021113"},{"doi-asserted-by":"publisher","key":"e_1_2_6_33_2","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_6_34_2","first-page":"564","article-title":"Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND (Fludarabine, Mitoxantrone, Dexamethasone) chemotherapy and rituximab monoclonal antibody therapy, with interferon maintenance","volume":"22","author":"McLaughlin P","year":"2003","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Result of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R\u2010MCP) versus MCP alone in untreated advanced indolent non\u2010Hodgkin'' lymphoma (NHL) and mantle\u2010cell\u2010lymphoma (MCL)","volume":"104","author":"Herold M","year":"2004","journal-title":"Blood."},{"doi-asserted-by":"publisher","key":"e_1_2_6_36_2","DOI":"10.1182\/blood-2004-08-3175"},{"doi-asserted-by":"publisher","key":"e_1_2_6_37_2","DOI":"10.1200\/JCO.2005.12.051"},{"doi-asserted-by":"publisher","key":"e_1_2_6_38_2","DOI":"10.1111\/j.1600-0609.1993.tb00165.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22740","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:22:45Z","timestamp":1760268165000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1002\/cncr.22740"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22740","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}